Effect of thalidomide combined with chemotherapy in treating extensive small-cell lung cancer
Hou Yan
Zhen Yingli
Wang Wei
Li Jidong
Xue Qingliang
Chen Weiqiang
Abstract：Objective To explore the recent clinical effect of thalidomide combined with chemotherapy in treating small-cell lung cancer.Methods Fifty patients with extensive small-cell lung cancer from March 2013 to March 2015 were randomly divided into observation group (25 cases) and control group (25 cases).Control group received conventional EP (etoposide + nedaplatin) chemotherapy,observation group was given thalidomide (50 mg,1 time/d) combined with EP chemotherapy;a cycle was 28 days.After 2 cycles of treatment,the levels of vascular endothelial growth factor (VEGF) in plasma were measured and compared between groups;the clinical effects and adverse reactions were compared between groups.Results The VEGF level in plasma before treatment was not significantly different between groups (P ＞ 0.05);the VEGF level in plasma in observation group was significantly lower than that in control group after treatment [(219 ± 10) ng/L vs (296 ± 16) ng/L] (P ＜0.05).The effective rate [76.0％ (19/25)] in observation group was significantly higher than that in control group [72.0％ (18/25)] (P ＞ 0.05).The incidence of myelosuppression was not significantly different between groups (P ＞ 0.05),the incidence of nausea and vomitting in observation group was significantly lower than that in control group [56.0％ (14/25) vs 84.0％ (21/25)] (P ＜0.05).Conclusion Thalidomide combined with EP chemotherapy can reduce the VEGF level in plasma,improve the clinical effective rate and reduce the incidence of nausea and vomiting in patients with extensive small-cell lung cancer.
Keywords：Small cell lung carcinomaThalidomideChemotherapyVascular endothelial growth factor
Publication Date：2016-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 809-812 )